Clinical observation of capecitabine monotherapy or combination regimen in the treatment of advanced breast cancer
10.3969/j.issn.1005-1678.2017.10.039
- VernacularTitle:卡培他滨单药或联合方案治疗晚期乳腺癌的临床疗效观察
- Author:
bin Ke ZHU
1
Author Information
1. 浙江大学明州医院 普外科
- Keywords:
capecitabine;
combination therapy;
docetaxel;
advanced breast cancer
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):98-99,101
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect and safety of patients with advanced breast cancer with capecitabine and gemcitabine combined with capecitabine treatment scheme. Methods 82 cases of patients with advanced breast cancer received treatment in our hospital from February 2014 to March 2016 were randomly selected and were randomly divided into control group and study group, 41 cases in each group.The control group using capecitabine monotherapy, the study group used capecitabine combined with docetaxel treatment. The therapeutic effects, safety and adverse reactions of the two groups were compared. Results The effective rate of treatment in the study group was 56.48 %, significantly better than that in the control group(34.28 %), the difference was statistically significant, The incidence of complications after treatment in the control group was 40.22 %, significantly higher than that in the study group (18.04 %), and the difference was statistically significant (P<0.05). Conclusion Capecitabine combined with docetaxel in the treatment of advanced breast cancer has good effect and low incidence of adverse reactions. It is worthy of recommendation and Application.
